NASDAQ:SPHS - Sophiris Bio Stock Price, Price Target & More

$2.17 +0.02 (+0.93 %)
(As of 04/20/2018 06:36 AM ET)
Previous Close$2.15
Today's Range$2.15 - $2.19
52-Week Range$1.80 - $2.74
Volume64,600 shs
Average Volume173,889 shs
Market Capitalization$65.64 million
P/E Ratio-5.41
Dividend YieldN/A
Beta1.34

About Sophiris Bio (NASDAQ:SPHS)

Sophiris Bio logoSophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.

Receive SPHS News and Ratings via Email

Sign-up to receive the latest news and ratings for SPHS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SPHS
CUSIPN/A
Phone858-777-1760

Debt

Debt-to-Equity Ratio0.84%
Current Ratio9.94%
Quick Ratio9.94%

Price-To-Earnings

Trailing P/E Ratio-5.41
Forward P/E Ratio-4.09
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.25 per share
Price / Book8.68

Profitability

EPS (Most Recent Fiscal Year)($0.40)
Net Income$-8,620,000.00
Net MarginsN/A
Return on Equity-108.75%
Return on Assets-44.37%

Miscellaneous

Employees6
Outstanding Shares30,110,000

How to Become a New Pot Stock Millionaire

Sophiris Bio (NASDAQ:SPHS) Frequently Asked Questions

What is Sophiris Bio's stock symbol?

Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS."

How were Sophiris Bio's earnings last quarter?

Sophiris Bio (NASDAQ:SPHS) posted its quarterly earnings data on Thursday, March, 29th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.02. View Sophiris Bio's Earnings History.

What price target have analysts set for SPHS?

3 Wall Street analysts have issued 1-year price objectives for Sophiris Bio's stock. Their forecasts range from $5.00 to $6.00. On average, they anticipate Sophiris Bio's share price to reach $5.6667 in the next twelve months. View Analyst Ratings for Sophiris Bio.

Who are some of Sophiris Bio's key competitors?

Who are Sophiris Bio's key executives?

Sophiris Bio's management team includes the folowing people:
  • Mr. Randall E. Woods, Pres, CEO & Director (Age 66)
  • Mr. Peter T. Slover CPA, Chief Financial Officer (Age 43)
  • Dr. Allison J. Hulme Ph.D., COO, Head of R&D and Director (Age 55)
  • Dr. Samuel R. Denmeade M.D., Chief Scientific Officer and Member of the Scientific Advisory Board
  • Dr. James Joseph Beesley BSc, DC, Sr. Director of Investor Relations (Age 46)

Has Sophiris Bio been receiving favorable news coverage?

News coverage about SPHS stock has been trending somewhat positive recently, Accern reports. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sophiris Bio earned a coverage optimism score of 0.09 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 47.00 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Sophiris Bio?

Shares of SPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sophiris Bio's stock price today?

One share of SPHS stock can currently be purchased for approximately $2.17.

How big of a company is Sophiris Bio?

Sophiris Bio has a market capitalization of $65.64 million. The biopharmaceutical company earns $-8,620,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Sophiris Bio employs 6 workers across the globe.

How can I contact Sophiris Bio?

Sophiris Bio's mailing address is 1258 PROSPECT STREET, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-777-1760 or via email at [email protected]


MarketBeat Community Rating for Sophiris Bio (SPHS)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  157 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  229
MarketBeat's community ratings are surveys of what our community members think about Sophiris Bio and other stocks. Vote "Outperform" if you believe SPHS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPHS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sophiris Bio (NASDAQ:SPHS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Sophiris Bio in the last 12 months. Their average twelve-month price target is $5.6667, suggesting that the stock has a possible upside of 161.14%. The high price target for SPHS is $6.00 and the low price target for SPHS is $5.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.6667$6.00$6.25$6.60
Price Target Upside: 161.14% upside200.00% upside175.33% upside207.55% upside

Sophiris Bio (NASDAQ:SPHS) Consensus Price Target History

Price Target History for Sophiris Bio (NASDAQ:SPHS)

Sophiris Bio (NASDAQ:SPHS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2018HC WainwrightSet Price TargetBuy$6.00LowView Rating Details
3/22/2018Maxim GroupSet Price TargetBuy$5.00LowView Rating Details
6/1/2017Rodman & RenshawReiterated RatingBuy$6.00HighView Rating Details
4/6/2017Piper JaffrayReiterated RatingOverweight$7.00MediumView Rating Details
11/11/2016Roth CapitalReiterated RatingBuy$8.00N/AView Rating Details
6/10/2016Echelon Wealth PartnersReiterated RatingBuy$5.00N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Sophiris Bio (NASDAQ:SPHS) Earnings History and Estimates Chart

Earnings by Quarter for Sophiris Bio (NASDAQ:SPHS)

Sophiris Bio (NASDAQ:SPHS) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.53 EPS
Next Year EPS Consensus Estimate: $-0.62 EPS

Sophiris Bio (NASDAQ SPHS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/29/2018Q4 2017($0.11)($0.13)ViewN/AView Earnings Details
11/9/2017Q3 2017($0.10)($0.11)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.09)($0.09)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.0930)($0.09)ViewN/AView Earnings Details
3/27/2017Q4 2016($0.11)($0.02)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.09)($0.15)ViewN/AView Earnings Details
8/9/2016Q2 2016($0.21)ViewN/AView Earnings Details
5/16/2016Q1($0.19)($0.13)ViewN/AView Earnings Details
3/23/2016Q4($0.15)ViewN/AView Earnings Details
11/16/2015Q3($0.22)ViewN/AView Earnings Details
8/13/2015Q2 2015($0.22)ViewN/AView Earnings Details
5/13/2015($0.30)($0.26)ViewN/AView Earnings Details
3/10/2015($0.47)($0.31)ViewN/AView Earnings Details
11/13/2014($0.54)($0.49)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.47)($0.53)ViewN/AView Earnings Details
5/13/2014Q114($0.50)($0.52)ViewN/AView Earnings Details
3/13/2014Q4 2013($0.33)($0.37)ViewN/AView Earnings Details
11/12/2013Q3 2013($0.43)($0.30)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Sophiris Bio (NASDAQ:SPHS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Sophiris Bio (NASDAQ SPHS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 6.37%
Insider Trading History for Sophiris Bio (NASDAQ:SPHS)
Institutional Ownership by Quarter for Sophiris Bio (NASDAQ:SPHS)

Sophiris Bio (NASDAQ SPHS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2014Boxer Capital, LlcMajor ShareholderSell881,479$0.61$537,702.19View SEC Filing  
11/14/2014Randall E WoodsInsiderBuy3,000$2.43$7,290.00View SEC Filing  
9/19/2014Gerald T ProehlDirectorBuy10,000$3.16$31,600.00View SEC Filing  
7/10/2014Randall E WoodsInsiderBuy1,000$2.65$2,650.00View SEC Filing  
7/9/2014Randall E WoodsInsiderBuy1,000$2.66$2,660.00View SEC Filing  
6/6/2014James L HeppellDirectorSell19,231$2.59$49,808.29View SEC Filing  
8/22/2013Randall E WoodsCEOBuy2,500$4.50$11,250.00View SEC Filing  
8/20/2013Peter T SloverCFOBuy4,680$4.25$19,890.00View SEC Filing  
8/19/2013Randall E WoodsCEOBuy10,000$4.29$42,900.00View SEC Filing  
8/16/2013Boxer Capital, LlcMajor ShareholderBuy1,600,000$5.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sophiris Bio (NASDAQ SPHS) News Headlines

Source:
DateHeadline
Sophiris Bio (SPHS) Expected to Announce Earnings of -$0.12 Per ShareSophiris Bio (SPHS) Expected to Announce Earnings of -$0.12 Per Share
www.americanbankingnews.com - April 18 at 11:22 PM
Sophiris Bio (SPHS) PT Set at $6.00 by Maxim GroupSophiris Bio (SPHS) PT Set at $6.00 by Maxim Group
www.americanbankingnews.com - April 10 at 5:03 PM
Sophiris Bio (SPHS) Upgraded by ValuEngine to "Sell"Sophiris Bio (SPHS) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - April 3 at 12:00 AM
Zacks: Brokerages Anticipate Sophiris Bio Inc (SPHS) to Post -$0.13 EPSZacks: Brokerages Anticipate Sophiris Bio Inc (SPHS) to Post -$0.13 EPS
www.americanbankingnews.com - April 1 at 11:24 PM
Sophiris Bio (SPHS) Presents At Needham and Company 17th Annual Healthcare Conference - SlideshowSophiris Bio (SPHS) Presents At Needham and Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:26 PM
Reviewing Sophiris Bio (SPHS) & Mediwound (MDWD)Reviewing Sophiris Bio (SPHS) & Mediwound (MDWD)
www.americanbankingnews.com - March 27 at 9:18 PM
SPHS: Topline Results from Phase 2b Study of Topsalysin at end of 2Q18SPHS: Topline Results from Phase 2b Study of Topsalysin at end of 2Q18
finance.yahoo.com - March 26 at 4:18 PM
Sophiris Bio (SPHS) Posts  Earnings Results, Misses Expectations By $0.02 EPSSophiris Bio (SPHS) Posts Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - March 22 at 11:50 PM
Sophiris Bio Reports Fourth Quarter and Full Year 2017 Financial ... - PR Newswire (press release)Sophiris Bio Reports Fourth Quarter and Full Year 2017 Financial ... - PR Newswire (press release)
www.prnewswire.com - March 22 at 4:23 PM
Maxim Group Analysts Give Sophiris Bio (SPHS) a $5.00 Price TargetMaxim Group Analysts Give Sophiris Bio (SPHS) a $5.00 Price Target
www.americanbankingnews.com - March 22 at 1:58 PM
HC Wainwright Analysts Give Sophiris Bio (SPHS) a $6.00 Price TargetHC Wainwright Analysts Give Sophiris Bio (SPHS) a $6.00 Price Target
www.americanbankingnews.com - March 22 at 11:52 AM
Sophiris Bio Reports Fourth Quarter and Full Year 2017 Financial Results and Key Corporate HighlightsSophiris Bio Reports Fourth Quarter and Full Year 2017 Financial Results and Key Corporate Highlights
finance.yahoo.com - March 21 at 4:23 PM
Sophiris Bio (SPHS) Set to Announce Quarterly Earnings on MondaySophiris Bio (SPHS) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - March 19 at 1:28 AM
Sophiris Bio Inc (SPHS) Expected to Post Earnings of -$0.10 Per ShareSophiris Bio Inc (SPHS) Expected to Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - March 15 at 9:12 PM
Sophiris Bio to Present at 17th Annual Needham Healthcare ConferenceSophiris Bio to Present at 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 15 at 4:55 PM
-$0.11 EPS Expected for Sophiris Bio Inc (SPHS) This Quarter-$0.11 EPS Expected for Sophiris Bio Inc (SPHS) This Quarter
www.americanbankingnews.com - February 26 at 9:12 PM
Sophiris Bio (SPHS) Stock Rating Reaffirmed by Maxim GroupSophiris Bio (SPHS) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - February 14 at 6:36 PM
Comparing Sophiris Bio (SPHS) & Patheon (PTHN)Comparing Sophiris Bio (SPHS) & Patheon (PTHN)
www.americanbankingnews.com - February 5 at 5:14 PM
Sophiris Bio (SPHS) & Theravance Biopharma (TBPH) Head-To-Head ContrastSophiris Bio (SPHS) & Theravance Biopharma (TBPH) Head-To-Head Contrast
www.americanbankingnews.com - January 28 at 7:12 PM
-$0.11 Earnings Per Share Expected for Sophiris Bio Inc (SPHS) This Quarter-$0.11 Earnings Per Share Expected for Sophiris Bio Inc (SPHS) This Quarter
www.americanbankingnews.com - January 24 at 9:12 AM
Sophiris Bio (SPHS) Given a $6.00 Price Target by HC Wainwright AnalystsSophiris Bio (SPHS) Given a $6.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - January 17 at 8:32 AM
Sophiris Bio to Participate in the 10th Annual Biotech Showcase ConferenceSophiris Bio to Participate in the 10th Annual Biotech Showcase Conference
finance.yahoo.com - December 27 at 9:12 AM
Reviewing Sophiris Bio (SPHS) & SciClone Pharmaceuticals (SCLN)Reviewing Sophiris Bio (SPHS) & SciClone Pharmaceuticals (SCLN)
www.americanbankingnews.com - December 22 at 5:54 PM
ValuEngine Upgrades Sophiris Bio (SPHS) to "Sell"ValuEngine Upgrades Sophiris Bio (SPHS) to "Sell"
www.americanbankingnews.com - December 16 at 3:36 PM
Sophiris Bio (SPHS) Reports Complete Enrollment in Phase 2b ... - StreetInsider.comSophiris Bio (SPHS) Reports Complete Enrollment in Phase 2b ... - StreetInsider.com
www.streetinsider.com - December 12 at 6:58 AM
Maxim Group Analysts Give Sophiris Bio (SPHS) a $6.00 Price TargetMaxim Group Analysts Give Sophiris Bio (SPHS) a $6.00 Price Target
www.americanbankingnews.com - December 11 at 5:08 PM
Sophiris Bio Announces Complete Enrollment in Phase 2b Topsalysin Study of Localized Prostate CancerSophiris Bio Announces Complete Enrollment in Phase 2b Topsalysin Study of Localized Prostate Cancer
finance.yahoo.com - December 11 at 3:20 PM
Sophiris Bio to Participate in the 29th Annual Piper Jaffray ... - PR Newswire (press release)Sophiris Bio to Participate in the 29th Annual Piper Jaffray ... - PR Newswire (press release)
www.prnewswire.com - November 28 at 11:00 AM
Sophiris Bio to Participate in the 29th Annual Piper Jaffray Healthcare ConferenceSophiris Bio to Participate in the 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 27 at 4:12 PM
Is Sophiris Bio Inc’s (SPHS) Balance Sheet Strong Enough To Weather A Storm?Is Sophiris Bio Inc’s (SPHS) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - November 22 at 8:26 AM
Is Sophiris Bio Inc’s (SPHS) Balance Sheet Strong Enough To Weather A Storm?Is Sophiris Bio Inc’s (SPHS) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - November 22 at 8:26 AM
SPHS: First Dosing in Phase 2b Trial of Topsalysin in Prostate Cancer Almost Complete; Data in 1H18SPHS: First Dosing in Phase 2b Trial of Topsalysin in Prostate Cancer Almost Complete; Data in 1H18
finance.yahoo.com - November 20 at 4:39 PM
Contrasting Sophiris Bio (SPHS) & Its RivalsContrasting Sophiris Bio (SPHS) & Its Rivals
www.americanbankingnews.com - November 19 at 1:16 PM
Sophiris Bio (SPHS) versus Amicus Therapeutics (FOLD) Critical ComparisonSophiris Bio (SPHS) versus Amicus Therapeutics (FOLD) Critical Comparison
www.americanbankingnews.com - November 19 at 5:22 AM
Zacks: Analysts Anticipate Sophiris Bio, Inc. (SPHS) to Post -$0.11 Earnings Per ShareZacks: Analysts Anticipate Sophiris Bio, Inc. (SPHS) to Post -$0.11 Earnings Per Share
www.americanbankingnews.com - November 15 at 11:38 AM
Analyzing Sophiris Bio (SPHS) and The CompetitionAnalyzing Sophiris Bio (SPHS) and The Competition
www.americanbankingnews.com - November 14 at 5:31 PM
Sophiris Bios (SPHS) Buy Rating Reaffirmed at HC WainwrightSophiris Bio's (SPHS) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - November 12 at 12:58 AM
Sophiris Bio Reports Third Quarter Financial Results and Key Corporate HighlightsSophiris Bio Reports Third Quarter Financial Results and Key Corporate Highlights
finance.yahoo.com - November 9 at 7:02 PM
Sophiris Bio, Inc. (SPHS) Set to Announce Quarterly Earnings on TuesdaySophiris Bio, Inc. (SPHS) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:52 AM
 Brokerages Expect Sophiris Bio, Inc. (SPHS) to Post -$0.10 Earnings Per Share Brokerages Expect Sophiris Bio, Inc. (SPHS) to Post -$0.10 Earnings Per Share
www.americanbankingnews.com - October 25 at 11:30 PM
Sophiris Bio, Inc. (SPHS) Receives Consensus Recommendation of "Buy" from AnalystsSophiris Bio, Inc. (SPHS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - October 4 at 6:02 PM
Sophiris Bio Says Patient Enrollment is Nearly Complete in Phase 2b Study of Treatment for Prostrate CancerSophiris Bio Says Patient Enrollment is Nearly Complete in Phase 2b Study of Treatment for Prostrate Cancer
www.nasdaq.com - October 3 at 12:45 PM
Sophiris Bio Provides Enrollment Update on Topsalysin Phase 2b Study in Localized Prostate CancerSophiris Bio Provides Enrollment Update on Topsalysin Phase 2b Study in Localized Prostate Cancer
finance.yahoo.com - October 3 at 12:45 PM
Maxim Group Reiterates Buy Rating for Sophiris Bio, Inc. (SPHS)Maxim Group Reiterates Buy Rating for Sophiris Bio, Inc. (SPHS)
www.americanbankingnews.com - October 2 at 11:24 AM
Sophiris Bio (SPHS) Announces Enrollment Update on Topsalysin Phase 2b Study in Localized Prostate Cancer - StreetInsider.comSophiris Bio (SPHS) Announces Enrollment Update on Topsalysin Phase 2b Study in Localized Prostate Cancer - StreetInsider.com
www.streetinsider.com - October 2 at 9:20 AM
HC Wainwright Reaffirms "Buy" Rating for Sophiris Bio, Inc. (SPHS)HC Wainwright Reaffirms "Buy" Rating for Sophiris Bio, Inc. (SPHS)
www.americanbankingnews.com - September 15 at 4:52 PM
Sophiris Bio Secures up to $10 Million in Term Loans from Silicon Valley BankSophiris Bio Secures up to $10 Million in Term Loans from Silicon Valley Bank
finance.yahoo.com - September 14 at 10:28 AM
Sophiris Bio, Inc. (SPHS) Receives Consensus Rating of "Buy" from AnalystsSophiris Bio, Inc. (SPHS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - September 9 at 2:50 PM
Sophiris Bio to Present at the Rodman & Renshaw 19th Annual Global Investment Conference - PR Newswire (press release)Sophiris Bio to Present at the Rodman & Renshaw 19th Annual Global Investment Conference - PR Newswire (press release)
www.prnewswire.com - August 19 at 7:44 AM
Sophiris Bio to Present at the Rodman & Renshaw 19th Annual Global Investment ConferenceSophiris Bio to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - August 18 at 7:27 AM

SEC Filings

Sophiris Bio (NASDAQ:SPHS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sophiris Bio (NASDAQ:SPHS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sophiris Bio (NASDAQ SPHS) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.